Kalorama Information studies on the pharmaceutical vaccines industry cover the global market opportunity in full, with data on major competitors, market direction, and the pediatric and adult segments. Kalorama reports examine the global vaccines market by region, including the US, South America, EU, Japan, India, and China, as well as by type, including hepatitis, pneumococcal, cervical cancer, and influenza, among others. Market share of major vaccine companies is reported as well.
- Display 15 Products per page
Published: March 25, 2011 | Price: $150.00 – $300.00
The Asian vaccine market is relatively small compared to its population, yet it is growing, and pharmaceutical manufacturers increasingly will look to boost sales from these emerging vaccine markets. The population of nearly 4 billion people throughout Asia accounts for more than half of the global population, yet currently it is Western markets which lead vaccine sales. This hasn't stopped companies from investing in Asian vaccine markets. The graying of the population in Asia and the growth in some regions...Published: August 29, 2014 | Price: $3,995.00 – $7,990.00
Biopharmaceutical and Vaccine Production Markets Biopharmaceutical and Vaccine Production Markets analyzes the entire manufacturing market for biologic drugs, including both outsourcing and costs by major maufacturers spending internally on biopharmaceutical and vaccine production. As part of its coverage, the following information is provided Market Size and Projections Vaccine Manufacturing Estimates Biologic Drug Methods Trend Analysis Types of Production Outsourcing Market Regulation of the Market Competitor Profiles This study contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other...Published: September 1, 2009 | Price: $2,995.00 – $5,990.00
With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports...Published: September 1, 2010 | Price: $1,500.00 – $3,000.00
Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer—the approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago. Even with achievements for some companies, numerous vaccines with apparently strong...Published: November 1, 2008 | Price: $3,995.00 – $7,990.00
It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products. There are several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming...Published: November 1, 2010 | Price: $995.00 – $3,000.00
The European vaccines market has demonstrated growth even through tough economic times. This has mainly been due to the introduction of vaccines in untapped disease markets and government’s acceptance and willingness to pay for new products. This has encouraged market participants to increase spending in research and development. This report, European Vaccine Markets, examines the market for vaccines used in humans for various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable;...Published: May 1, 2010 | Price: $500.00 – $2,400.00
The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world, they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths. Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly, what are lessons for future pandemic and...Published: October 18, 2012 | Price: $3,995.00 – $7,990.00
Vaccines are an important part of the business model of top pharmaceutical companies. The success of several recent vaccine product introductions has been of great interest to pharma R&D efforts. The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth in many categories through 2011, declines in others, and this is expected to continue through the forecast period. Growth is being fueled...Published: July 1, 2011 | Price: $150.00 – $300.00
As researchers work to improve drug properties through drug design and molecular modeling, the line between drug delivery and drug substance will become more and more elusive in the near future, as shown in the analysis in this report. Consequently, in the next decade, drug delivery technologies will be a focal point of competition within the pharmaceutical industry and the needle-free drug delivery market will continue to grow rapidly. This Kalorama Information report, Needle-Free Drug Delivery: The Market for Alternatives...Published: January 1, 2004 | Price: $3,500.00 – $7,000.00
The cost of drug development has soared during the past ten years compelling pharmaceutical and biotechnology companies to look for new, smarter ways of conducting clinical research. Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. This industry has evolved from providing limited clinical trial services...Published: November 1, 2006 | Price: $1,200.00 – $7,000.00
Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field. Specific segments covered in the report include: Cervical cancer, Colorectal cancer, Lung cancer, Lymphoma, Melanoma, Prostate cancer, and Other cancers for which vaccines are in development. Each market segment provides an overview, descriptions of products available...Published: December 4, 2012 | Price: $500.00 – $1,000.00
This Kalorama Information report – The Next Wave in Cancer Treatment--Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including: Breast Colorectal Head/Neck Kidney Leukemia Liver Lung Melanoma Ovarian Pancreatic Prostate Stomach The report covers both currently marketed and late stage development kinase inhibitors for cancer treatment. Revenues for this market segment were generated using dollar...Published: November 12, 2015 | Price: $2,100.00 – $4,200.00
This report, the World Market for Cancer Therapeutics presents a detailed picture of the market for cancer drugs, with a focus on novel therapies. The market analysis in this report includes analysis of products avaiable for each cancer type (Breast Cancer, Lung Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Colon Cancer and Other types) including Monoclonal Antibodies, Tyrosine Kinase, Inhibitors, Cancer Vaccines, Cytokines, Gene Therapy, Traditional Chemotherapy. The report has a special emphasis on novel treatments and provides an overview of...Published: November 1, 2004 | Price: $3,500.00 – $7,000.00
This report covers pediatric and adult preventive vaccine products and provides an analysis of therapeutic vaccines for cancer treatment. In assessing the market for vaccine products, Kalorama Information provides sales data for the 2001-2003 historical years, the 2004 base year, and the 2001 through 2010 forecast years. Revenues are expressed in terms of manufacturers’ annual sales and in current U.S. dollars. The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources...Published: September 23, 2022 | Price: $5,000.00 – $10,000.00
V A C C I N E M A R K E T E X C E E D S $200 B I L L I O N In 2022, the global market for preventive vaccines is valued at $202.6 billion. That's up from $34.1 billion in 2017, and just $25 billion in 2010. Infectious diseases are some of the deadliest diseases that pose significant risk to human life. Sales increased from $127.6 billion in 2021 to $202.6 billion in...